Form 4: Kairos Pharma VP of Research and Development Acquires Shares

Kairos Pharma's VP of Research and Development, Ramachandran Murali, purchased 200 shares of common stock at $1.59 per share on November 25, 2024.

Summary

• Ramachandran Murali, VP of Research and Development at Kairos Pharma, acquired 200 shares of the company's common stock.
• The transaction occurred on November 25, 2024.
• The purchase price was $1.59 per share.
• Following the transaction, Mr. Murali directly owns 133,057 shares of Kairos Pharma stock.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, as it is a standard regulatory filing. The purchase of shares by an officer is a slightly positive signal, but the volume is small.

Positives

• The purchase of shares by a company officer can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common when company insiders trade shares. It provides transparency into the trading activities of company officers.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The purchase of 200 shares is a relatively small transaction compared to typical insider trading volumes, but it is still a relevant disclosure.

Stakeholder Impact

• The purchase of shares by a company officer may have a slightly positive impact on shareholder confidence.

Key Dates

Keywords

Kairos Pharma, insider trading, stock purchase, Form 4, Ramachandran Murali, KAPA, share acquisition